CALCRL and migraine disorder: Among anti-CGRP(r) mAbs, erenumab (in monthly doses of 70 or 140 mg), a fully human mAb directed against CGRPr, was the first approved specific preventive treatment for migraine, whose efficacy and safety have been demonstrated in both EM and CM [9,10].